KR101298507B1 - 4-(벤즈이미다졸릴메틸아미노)벤즈아미딘의 제조방법 - Google Patents

4-(벤즈이미다졸릴메틸아미노)벤즈아미딘의 제조방법 Download PDF

Info

Publication number
KR101298507B1
KR101298507B1 KR1020077001725A KR20077001725A KR101298507B1 KR 101298507 B1 KR101298507 B1 KR 101298507B1 KR 1020077001725 A KR1020077001725 A KR 1020077001725A KR 20077001725 A KR20077001725 A KR 20077001725A KR 101298507 B1 KR101298507 B1 KR 101298507B1
Authority
KR
South Korea
Prior art keywords
group
formula
compound
acetic acid
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077001725A
Other languages
English (en)
Korean (ko)
Other versions
KR20070029817A (ko
Inventor
게오르크 체르반
아른트 하우스헤어
케르스틴 슐라르브
하인츠-페터 슈미트
뵈른 바이엘
군터 코흐
라이너 함
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101298507(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20070029817A publication Critical patent/KR20070029817A/ko
Application granted granted Critical
Publication of KR101298507B1 publication Critical patent/KR101298507B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
KR1020077001725A 2004-06-25 2005-06-18 4-(벤즈이미다졸릴메틸아미노)벤즈아미딘의 제조방법 Expired - Lifetime KR101298507B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04014917.1 2004-06-25
EP04014917A EP1609784A1 (de) 2004-06-25 2004-06-25 Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
PCT/EP2005/006586 WO2006000353A1 (de) 2004-06-25 2005-06-18 Verfahren zur herstellung von 4-(benzimidazolylmethylamino)- benzamidinen

Publications (2)

Publication Number Publication Date
KR20070029817A KR20070029817A (ko) 2007-03-14
KR101298507B1 true KR101298507B1 (ko) 2013-08-22

Family

ID=34925482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077001725A Expired - Lifetime KR101298507B1 (ko) 2004-06-25 2005-06-18 4-(벤즈이미다졸릴메틸아미노)벤즈아미딘의 제조방법

Country Status (20)

Country Link
US (2) US7202368B2 (https=)
EP (2) EP1609784A1 (https=)
JP (1) JP5073486B2 (https=)
KR (1) KR101298507B1 (https=)
CN (1) CN1972919B (https=)
AR (1) AR049410A1 (https=)
AU (1) AU2005256424B2 (https=)
BR (1) BRPI0511318B8 (https=)
CA (1) CA2570499C (https=)
DK (1) DK1761510T3 (https=)
ES (1) ES2543982T3 (https=)
HU (1) HUE027198T2 (https=)
IL (2) IL180247A (https=)
MX (1) MXPA06015210A (https=)
NZ (1) NZ552809A (https=)
PL (1) PL1761510T3 (https=)
RU (1) RU2401264C2 (https=)
TW (1) TWI364417B (https=)
WO (1) WO2006000353A1 (https=)
ZA (1) ZA200609918B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091396A1 (ko) 2018-10-29 2020-05-07 주식회사 엘지화학 전기화학소자용 분리막 및 이를 제조하는 방법

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
WO2008043759A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006054005A1 (de) * 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
CZ305085B6 (cs) 2008-03-14 2015-04-29 Zentiva, K.S. Způsob přípravy dabigatranu
RU2010143901A (ru) * 2008-03-28 2012-05-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения композиций дабигатрана для перорального введения
NZ588488A (en) * 2008-06-16 2012-08-31 Boehringer Ingelheim Int Method for producing an intermediate product of dabigatran etexilate
BRPI0915942A2 (pt) * 2008-07-14 2019-04-09 Boehringer Ingelheim International Gmbh método para produção de compostos medicinais contendo dabigatrana
CZ2008669A3 (cs) * 2008-10-24 2010-05-05 Zentiva, A. S. Zpusob prípravy dabigatranu a jeho meziprodukty
CN102050815B (zh) * 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 作为前药的达比加群的酯衍生物
CN102050814B (zh) * 2009-11-06 2014-05-28 北京美倍他药物研究有限公司 达比加群的酯衍生物
US8399678B2 (en) * 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate
WO2012004396A2 (en) 2010-07-09 2012-01-12 Esteve Química, S.A. Process of preparing a thrombin specific inhibitor
JP2013531004A (ja) 2010-07-09 2013-08-01 エステヴェ キミカ， エス．エー． トロンビン特異的インヒビターの調製のための中間体及び方法
PL2603503T3 (pl) 2010-09-27 2015-12-31 Ratiopharm Gmbh Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania
WO2012077136A2 (en) * 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
EP2522662A1 (en) 2011-05-11 2012-11-14 Medichem, S.A. Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers
WO2013111163A2 (en) 2012-01-20 2013-08-01 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP2834224B1 (en) 2012-04-02 2018-06-06 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
WO2014020555A2 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited An improved process for the preparation of dabigatran etexilate mesylate
IN2015DN02616A (https=) * 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
US10077251B2 (en) 2012-10-29 2018-09-18 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of Dabigatran Etexilate and its intermediates
US9533971B2 (en) 2012-10-29 2017-01-03 Biophore India Pharmaceuticals Pvt. Ltd Process for the synthesis of dabigatran and its intermediates
WO2014178017A1 (en) * 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN103626740B (zh) * 2013-12-05 2015-02-04 南京欧信医药技术有限公司 一种化合物的合成方法
CN103772358A (zh) * 2014-01-07 2014-05-07 万特制药(海南)有限公司 一种制备达比加群酯的合成方法
IN2014MU00675A (https=) 2014-02-26 2015-10-23 Megafine Pharma P Ltd
CN105461686A (zh) * 2014-08-25 2016-04-06 江苏豪森药业股份有限公司 制备高纯度甲磺酸达比加群酯晶型的方法
CN104910047B (zh) * 2015-05-11 2017-06-06 常州市阳光药业有限公司 达比加群酯中间体的制备方法
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN116178252A (zh) * 2022-07-26 2023-05-30 浙江海翔药业股份有限公司 一种甲磺酸达比加群酯的原料杂质及其制备方法和用途
CN116354952A (zh) * 2023-01-06 2023-06-30 宿迁盛基医药科技有限公司 一种达比加群酯关键中间体的合成工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000071066A (ko) * 1997-02-18 2000-11-25 클래스 하인츠-게르트 이치환된 비사이클릭 헤테로사이클, 이의 제조방법 및 약제로서의 이의 용도
KR20010083087A (ko) * 1998-07-04 2001-08-31 클래스 하인츠-게르트 벤즈이미다졸, 이의 제조방법 및 약제로서의 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
US6248770B1 (en) * 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
DE19924818A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide
DE19962329A1 (de) * 1999-12-23 2001-06-28 Boehringer Ingelheim Pharma Benzimidazole, deren Herstellung und deren Verwendung als Arzneimittel
US6451832B2 (en) * 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
EP1574516A1 (en) * 2004-03-05 2005-09-14 Sanofi-Aventis Antithrombotic compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000071066A (ko) * 1997-02-18 2000-11-25 클래스 하인츠-게르트 이치환된 비사이클릭 헤테로사이클, 이의 제조방법 및 약제로서의 이의 용도
KR20010083087A (ko) * 1998-07-04 2001-08-31 클래스 하인츠-게르트 벤즈이미다졸, 이의 제조방법 및 약제로서의 이의 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091396A1 (ko) 2018-10-29 2020-05-07 주식회사 엘지화학 전기화학소자용 분리막 및 이를 제조하는 방법

Also Published As

Publication number Publication date
EP1761510A1 (de) 2007-03-14
IL180247A0 (en) 2007-07-04
CA2570499A1 (en) 2006-01-05
NZ552809A (en) 2009-06-26
HUE027198T2 (en) 2016-08-29
IL211491A0 (en) 2011-05-31
WO2006000353A1 (de) 2006-01-05
ES2543982T3 (es) 2015-08-26
IL180247A (en) 2011-11-30
EP1609784A1 (de) 2005-12-28
KR20070029817A (ko) 2007-03-14
IL211491A (en) 2012-05-31
US20060004064A1 (en) 2006-01-05
ZA200609918B (en) 2008-10-29
MXPA06015210A (es) 2007-03-15
BRPI0511318B1 (pt) 2018-02-14
CN1972919B (zh) 2012-06-27
PL1761510T3 (pl) 2015-10-30
BRPI0511318B8 (pt) 2021-05-25
RU2401264C2 (ru) 2010-10-10
US7202368B2 (en) 2007-04-10
CA2570499C (en) 2013-08-06
AR049410A1 (es) 2006-07-26
BRPI0511318A (pt) 2007-12-04
TWI364417B (en) 2012-05-21
JP2008503519A (ja) 2008-02-07
US7459566B2 (en) 2008-12-02
CN1972919A (zh) 2007-05-30
EP1761510B1 (de) 2015-05-13
US20070149589A1 (en) 2007-06-28
RU2007102631A (ru) 2008-07-27
AU2005256424A1 (en) 2006-01-05
DK1761510T3 (en) 2015-08-17
TW200613287A (en) 2006-05-01
AU2005256424B2 (en) 2011-12-08
JP5073486B2 (ja) 2012-11-14

Similar Documents

Publication Publication Date Title
KR101298507B1 (ko) 4-(벤즈이미다졸릴메틸아미노)벤즈아미딘의 제조방법
KR101408709B1 (ko) 4-(벤즈이미다졸릴메틸아미노)-벤즈아미드 및 이의 염의개선된 제조 방법
KR101411961B1 (ko) 4-(벤즈이미다졸릴메틸아미노)-벤즈아미드의 염을 제조하기위한 개선된 방법
MX2008007170A (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160805

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170804

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250619

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION